CliffBio
biologic

Kepivance

palifermin

Loss of exclusivityDecember 2016projected — 12-year biologic exclusivity estimate
CompanySwedish Orphan Biovitrum AB (publ)

Drug detail

Brand nameKepivance
Active ingredientpalifermin
Strength6.25MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2004
Marketing statusRx

More from Swedish Orphan Biovitrum AB (publ)

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Kepivance patent cliff — loss of exclusivity December 2016 | CliffBio